Specialty Pharmaceutical Hub Services/Patient Assistance Providers News Roundup: June 2024


AMI’s annual Specialty Hub Service Providers Report provides comprehensive business intelligence on more than 75 companies


Prime Therapeutics LLC and Magellan Rx Management (Prime/MRx) launched Pharmacy Match, a technology-enabled specialty pharmacy solution designed to drive competition through an expanded specialty pharmacy network and to lower drug costs for plan sponsors.  Pharmacy Match, powered byFree Market Health’s proprietary, cloud-based technology platform, helps members smoothly flow through their specialty journey. To help create a frictionless experience, the real-time referral feature comparison shops the market and helps ensure members’ specialty medications are provided by the specialty pharmacy best suited to meet their needs. And to help alleviate uncertainty, Pharmacy Match members who are new to therapy are engaged early to help ensure an uninterrupted journey. Through this platform, each specialty claim is tracked to fulfillment, elevating the experience for plan sponsors and their members.


IntegriChain, delivering pharma’s comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, announced the acquisition of BridgeView Data Solutions, the commercial data warehouse and data aggregation assets of BridgeView Life Sciences LLC (formerly Coeus Solutions). This transaction allows IntegriChain and BridgeView to offer pharmaceutical manufacturers best-in-class first- and third-party data aggregation, add AI-assisted data exploration capabilities, extend its reach through field intelligence and alerting, deliver new commercial data warehouse (CDW) offerings, and deepen its strength in commercial data strategy. IntegriChain will offer BridgeView’s DataBridge commercial data warehouse, delivering a flexible, scalable platform for data synthesis, enrichment, and application. DataBridge ingests, stores, governs, and analyzes data from heterogeneous sources, including existing databases, business applications, and industry-standard solutions.


Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, announced that it has earned the prestigious Leaders in Performance Measurement award from URAC, the nation’s largest independent health care accreditation organization. URAC recognizes leaders who demonstrate commitment to improving healthcare quality through performance measurement and continuous quality improvement (CQI) to enhance the health and well-being of the populations they serve. Optime Care specialists are expert communicators who optimize the patient journey, providing clinical guidance and valuable assistance to patients and families. They streamline care coordination, help with insurance coverage, address financial needs and identify financial assistance programs to improve patient access to therapies.


Permira, the global investment firm, and PharmaCord LLC, a leading provider of patient services for the pharmaceutical industry, announced that a company backed by the Permira funds has signed a definitive agreement to make a substantial investment in PharmaCord. Founder and Chief Executive Officer Nitin Sahney and the management team will continue to lead PharmaCord and will remain significant investors in the Company alongside the Permira funds. Terms of the transaction were not disclosed. PharmaCord’s comprehensive solutions support the patient journey for specialty medications through a range of services that raise awareness, facilitate access to treatment, improve affordability and promote therapy adherence. A leading tech-enabled player in the space, PharmaCord has relationships with over 30 pharmaceutical company clients and supports over 100 pharmaceutical products through its various programs.


United BioSource LLC (UBC), a leading provider of evidence development solutions, and Thread, a leading decentralized research, electronic clinical outcome assessment (eCOA) and consulting services provider, announced the expansion of their SitePlus solution. This joint offering, the outcome of a successful six-year working relationship, has provided early recruitment and retention success for biopharma customers since its March 2023 launch. UBC and Thread have now expanded the solution to offer additional central site services and technology features for both post-approval research and Phase II/III interventional clinical trials. United BioSource LLC (UBC) is the leading provider of evidence development solutions with expertise in uniting evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions.